Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 49.605 mg (equivalent: pioglitazone, qty 45 mg) - tablet, uncoated - excipient ingredients: carmellose calcium; hyprolose; lactose monohydrate; magnesium stearate - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - pioglitazone hydrochloride, quantity: 33.07 mg (equivalent: pioglitazone, qty 30 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; carmellose calcium; hyprolose - treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise: as monotherapy; as dual therapy to improve glycaemic control: in combination with metformin or sulfonylurea, in combination with insulin; as triple therapy to improve glycaemic control: in combination with metformin and sulfonylurea.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 200 mg - capsule, hard - excipient ingredients: carrageenan; titanium dioxide; sodium lauryl sulfate; gelatin; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow; purified talc - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - celecoxib, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; carrageenan; gelatin; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; indigo carmine; titanium dioxide; purified talc; colloidal anhydrous silica - for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.,for the treatment of primary dysmenorrhoea in adults.,for the short-term treatment of acute pain in adults following surgery or musculoskeletal and/or soft tissue injury.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; iron oxide yellow; calcium hydrogen phosphate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; calcium hydrogen phosphate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; quinoline yellow; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: quinoline yellow; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).